1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,828 | 1,002 | 22:58 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | NFL Biosciences Clarifies the Objectives and Evaluation Criteria for a Predictive Biomarker Associated With NFL-101 | 197 | Business Wire | Regulatory News:
NFL BIOSCIENCES (Euronext Growth Paris FR0014003XT0 ALNFL, a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, today clarifies... ► Artikel lesen | |
| 04.05. | NFL Biosciences: International Scientific Community's Interest in NFL-102 for Smoking Cessation Confirmed by the Selection of Its Work at Two Leading Conferences | 282 | Business Wire | Regulatory News:
NFL BIOSCIENCES (Euronext Growth Paris FR0014003XT0 ALFNL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, announces that... ► Artikel lesen | |
| 15.04. | NFL Biosciences Presents Its 2025 Annual Results and Provides an Update on Its Clinical Progress Driven by a New Paradigm in Smoking Cessation | 393 | Business Wire | Emergence of a new paradigm in smoking cessation, based on an in-depth understanding of the biological mechanisms of addiction, with the ambition to achieve superior efficacy compared with current... ► Artikel lesen | |
| 15.04. | NFL Biosciences Strengthens Its Cash Position by €2.6 Million Through Bond Financing Subscribed by a Group of European Institutional Investors | 454 | Business Wire | A €2.6 million bond financing has been secured with a group of European investors including Vester Finance, a shareholder of the Company Cash runway is immediately extended until the third... ► Artikel lesen | |
| 07.04. | A New Paradigm in Tobacco and Nicotine Addiction: NFL Biosciences Demonstrates the Mechanism of Action of NFL-102 in a Video | 307 | Business Wire | A breakthrough mechanism of action targeting neural plasticity associated with addiction, particularly through the CREB regulator, a key factor in relapse An educational video illustrating... ► Artikel lesen | |
| 11.03. | Bpifrance Renews Its Confidence in NFL Biosciences Through the Granting of a €500,000 Loan | 484 | Business Wire | €500,000 loan with a 36-month repayment deferral Financial support to prepare the submission of the Phase 2 clinical trial application for NFL-102 expected in mid-2026 Strengthening... ► Artikel lesen | |
| 19.02. | NFL Biosciences Publishes Its 2026 Financial Agenda | 378 | Business Wire | Regulatory News:
NFL BIOSCIENCES (Euronext Growth Paris FR0014003XT0 ALFNL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, presents its financial agenda... ► Artikel lesen | |
| 26.01. | NFL Biosciences SA: NFL Biosciences Significantly Raises Its Efficacy Targets for Smoking Cessation | 364 | Business Wire | In-depth understanding of the mechanism of action of its drug candidates based on new data Enhanced clinical development strategy based on these advances, targeting clinical efficiencies... ► Artikel lesen | |
| NFL BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 08.12.25 | NFL Biosciences Obtains Complementary Characterization Results for NFL-101, its first-in-class Drug Candidate for Smoking Cessation, and Prepares a New Patent Application | 317 | Business Wire | These results represent the first scientific milestone expected by regulatory agencies and potential pharmaceutical partners New patent application currently in preparation Results... ► Artikel lesen | |
| 12.11.25 | NFL Biosciences SA: NFL Biosciences Presents the Agenda for Results Expected by Regulatory Agencies and Potential Pharmaceutical Partners | 405 | Business Wire |
Regulatory News:
NFL Biosciences SA (Euronext Growth Paris FR0014003XT0 ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addiction, today presents... ► Artikel lesen | |
| 20.10.25 | NFL Biosciences Outlines Its Development Plan for NFL-101 in Smoking Cessation Following Receipt of Scientific Advice From Several European Agencies and the U.S. FDA | 484 | Business Wire | Confirmation by several European agencies and the U.S. FDA of the relevance of the continuous abstinence validation criteria which showed statistical significance (p=0.02) in the Phase 2 CESTO... ► Artikel lesen | |
| 16.10.25 | NFL Biosciences Reports Its 2025 Half-Year Results and Provides an Update on Its Development | 554 | Business Wire | Additional studies and analyses confirming the excellent safety profile of NFL-101, its immunological action associated with smoking abstinence, and its rapid and sustained effects on brain regions... ► Artikel lesen | |
| 01.09.25 | NFL Biosciences Announces the Publication of the Results of Its Phase II Clinical Trial CESTO II Evaluating NFL-101 in Smoking Cessation in Nicotine & Tobacco Research, the Official Journal of the Society for Research on Nicotine and Tobacco (SRNT) | 796 | Business Wire | The SRNT, the world's leading scientific society dedicated to nicotine and tobacco research, publishes the results of the CESTO II study in its reference journal, thereby ensuring their optimal... ► Artikel lesen | |
| 28.07.25 | NFL Biosciences Announces a Scientific Collaboration with McLean Hospital (Boston, USA) to Further Investigate the Mechanism of Action of NFL-101 | 428 | Business Wire | Regulatory News:
NFL BIOSCIENCES (Euronext Growth Paris FR0014003XT0 ALFNL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addiction, today announces... ► Artikel lesen | |
| 22.07.25 | NFL Biosciences Secures Initial Non-Dilutive Funding of €1.2 Million, Adding to Its Recent Capital Increase, to Advance the Development of NFL-101, Its First-in-Class Treatment for Tobacco Addiction | 413 | Business Wire | A €600,000 "Innovation Advance" repayable advance granted by Bpifrance
€600,000 in bank loans granted by Société Générale and Banque Populaire, the company's long-standing banking partners... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,350 | -1,56 % | Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht | DJ Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht
DOW JONES--Die Aktionäre von Qiagen können sich über eine höhere Dividende freuen. Wie es in der Einladung zur Hauptversammlung... ► Artikel lesen | |
| EVOTEC | 4,540 | -10,63 % | EQS-News: Evotec SE: Evotec gibt Ergebnisse für das erste Quartal 2026 bekannt: Transformation gewinnt an Dynamik | EQS-News: Evotec SE
/ Schlagwort(e): Quartalsergebnis/Quartals-/Zwischenmitteilung
Evotec gibt Ergebnisse für das erste Quartal 2026 bekannt: Transformation gewinnt an Dynamik... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,220 | +2,24 % | H.C. Wainwright is Bullish on Relay Therapeutics, Inc. (RLAY) | ||
| TARSUS PHARMACEUTICALS | 64,66 | +8,07 % | Tarsus reiterates 2026 net product sales guidance of $670M-$700M as XDEMVY posts $145.4M in Q1 sales | ||
| BICARA THERAPEUTICS | 20,990 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026 Long-term follow-up... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 21,690 | +4,83 % | Arcutis Q1 2026: Umsatz steigt um 65 %, doch Expansionskosten führen zu höheren Verlusten | ||
| PRAXIS PRECISION MEDICINES | 346,46 | +0,95 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,330 | +1,30 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update | ||
| TANGO THERAPEUTICS | 25,510 | +8,55 % | Stifel Remains Bullish on Tango Therapeutics (TNGX) | ||
| C4 THERAPEUTICS | 3,660 | +15,46 % | C4 Therapeutics, Inc.: C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab... ► Artikel lesen | |
| BIONTECH | 78,95 | -1,07 % | Curevac-Gründer wirft Biontech Täuschung vor | TÜBINGEN/MAINZ (dpa-AFX) - Nach der Übernahme des Biotechunternehmens Curevac durch Biontech wirft Curevac-Gründer Ingmar Hoerr dem Konkurrenten Täuschung vor. Hintergrund sind die Schließungspläne... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 117,82 | +8,44 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy | Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population... ► Artikel lesen | |
| BIOVENTUS | 10,400 | +2,56 % | Bioventus, Inc.: Bioventus Reports First Quarter Financial Results | Q1 reported revenue of $132.1 million increased 7%First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted shareNon-GAAP earnings* of $0.15... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 26,850 | -8,24 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | - NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of December 22, 2026 - - Conference call today at 4:30 p.m. ET - RADNOR, Pa., May 06, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| ERASCA | 10,450 | +0,67 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen |
NFL BIOSCIENCES SA gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,806 Euro und damit -7,67 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NFL BIOSCIENCES SA finden Sie auf Wallstreet Online.